# Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

> **NCT00609011** · PHASE1,PHASE2 · COMPLETED · sponsor: **Myrexis Inc.** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** MPC-6827 + Temozolomide

## Key facts

- **NCT ID:** NCT00609011
- **Lead sponsor:** Myrexis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2010-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00609011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00609011, "Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00609011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*